Effect of lifestyle intervention plus rosiglitazone or placebo therapy on left ventricular mass assessed with cardiovascular magnetic resonance in the metabolic syndrome

Table 3 Multivariable association clinical and laboratory variables and LV mass-I reduction

		Β-coefficient	P-value^a	R²	P-value^b
Model 1				0.421	0.002
	Rosiglitazone therapy	3.6 (1.5-5.7)	0.002
Model 2				0.516	0.002
	Rosiglitazone therapy	3.2 (1.1-5.3)	0.006
	Δ systolic blood pressure	-0.03 (-0.12-0.06)	0.5
	Δ diastolic blood pressure	-0.07 (-0.27-0.12)	0.4
	Δ triglyceride	-0.68 (-.2-1.8)	0.6
Model 3				0.611	0.01
	Rosiglitazone therapy	3.7 (1.7-5.7)	0.003
	Δ systolic blood pressure	-0.01 (-0.09-0.08)	0.9
	Δ diastolic blood pressure	-0.11 (-0.29-0.07)	0.3
	Δ triglyceride	-1.0 (-3.3-1.3)	0.4
	LV mass-I at baseline	-0.1 (-0.2-0.3)	0.2

^a Level of significance of the association between the separate components of the model and reduction in LV mass-I.
^b Level of significance of the model.
LV mass-I: left ventricular mass indexed for body surface area

ISSN: 1532-429X